What the FDA labels say about taking them together
Insulin aspart and pramlintide
Insulin aspart's FDA label of June 21, 2023 names pramlintide in its drug interactions section; pramlintide's label does not name insulin aspart itself but warns about its class (insulin analogs). The insulin aspart label: “… disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. …”
Check it at the source: the insulin aspart FDA label on DailyMed (effective June 21, 2023, Novo Nordisk); the pramlintide FDA label on DailyMed (effective December 18, 2019, AstraZeneca Pharmaceuticals LP).
What does the insulin aspart label say about pramlintide?
Insulin aspart label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose reductions and increased frequency of glucose monitoring may be required when FIASP is co-administered with these drugs.
Source: FDA drug label (Insulin Aspart, BLA020986), Novo Nordisk Pharma, Inc., effective February 28, 2023 (SPL set bee5b358-c863-420b-be73-ced2e920c499), via openFDA
Source: FDA drug label (Fiasp), Novo Nordisk, effective June 21, 2023 (SPL set 834e7efc-393f-4c55-9125-628562a8a5cf), via openFDA; the full label on DailyMed
What does the pramlintide label say about insulin aspart?
Pramlintide's label does not name insulin aspart itself; it warns about its class (insulin analogs):
Pramlintide label, boxed warningSEVERE HYPOGLYCEMIA SYMLIN use with insulin increases the risk of severe hypoglycemia, particularly in patients with type 1 diabetes.
Pramlintide label, boxed warningAppropriate patient selection, careful patient instruction, and insulin dose reduction are critical elements for reducing this risk.
Source: FDA drug label (SymlinPen), AstraZeneca Pharmaceuticals LP, effective December 18, 2019 (SPL set 4aea30ff-eb0d-45c1-b114-3127966328ff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin aspart | Pramlintide | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $6.95 per mL 100 unit/mL vial | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once